<DOC>
	<DOCNO>NCT01097512</DOCNO>
	<brief_summary>In clinical practice research , combination anticancer agent often use improve efficacy treatment . In vitro vivo experiment show additive-synergistic anti-tumour effect AS703569 treatment combine gemcitabine . Specifically , additive-synergistic anti-tumour effect notice two agent give sequentially concomitantly i.e . AS703569 give day day gemcitabine . This trial design investigate parallel two regimen test sequential administration AS703569 either day gemcitabine infusion , ( Regimen 1 ) day ( Regimen 2 ) .</brief_summary>
	<brief_title>AS703569 Gemcitabine Combination Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically/cytologically confirm diagnosis measurable assessable malignancy , meet one follow condition : Subject tumour gemcitabine approve , Subject tumour gemcitabine consider standard care , Subject tumour type either refractory intolerant accept standard treatment . Male female least 18 year age . Life expectancy least 3 month . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 2 . No 3 prior chemotherapy regimens advanced/metastatic disease . At least 4 week since last chemotherapy , hormonal therapy , immunotherapy , biological pharmacological investigational treatment radiotherapy ( 6 week washout nitrosoureas mitomycin C , 5 halflives noncytotoxics ) . Subjects chronic hormonal therapy may continue treatment unchanged . Adequate renal , hepatic bone marrow function ( assessed 7 day inclusion trial ) define : Serum creatinine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>AS703569</keyword>
	<keyword>MSC1992371A</keyword>
	<keyword>Aurora kinase inhibitor</keyword>
	<keyword>Cancer treatable gemcitabine</keyword>
</DOC>